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The formation of new lymphatic vessels, or lymphangio-
genesis, is a natural process involved in tissue repair and
in the resolution of inflammatory reactions. In some
cancers, this process is exploited by the tumor to pro-
mote its growth and its metastatic dissemination. Our
group recently identified a role for the CD73-adenosine
pathway in tumor angiogenesis. As angiogenesis and
lymphangiogenesis are similar processes, often occurring
in parallel, we suspect that the CD73-adenosine pathway
could have a role in the regulation of lymphangiogenesis
during inflammatory reactions and in the tumor
microenvironment.
To confirm this hypothesis, we used in vivo models of
inflammatory lymphangiogenesis induced by the adminis-
tration of lipopolysaccharide (LPS) or Incomplete Freund’s
Adjuvant (IFA) in the peritoneal cavity of mice. These two
models of peritonitis trigger the formation of new lympha-
tics in the diaphragm that can be analyzed by flow cyto-
metry. To study tumor lymphangiogenesis, we used a
B16F10 melanoma model implanted in the mouse foot
pad thereby allowing the analysis of tumor cell dissemina-
tion in the popliteal draining lymph node.
Using A2A-deficient mice, our results demonstrate that
the A2A receptor is required for the proper formation of
new lymphatic vessels following LPS and IFA administra-
tion. Using multicolor flow cytometry we were able to
show that A2A-deficiency impairs both the formation of
new lymphatic capillaries from pre-existing vessels and
the transdifferentiation of pro-inflammatory myeloid
cells into lymphatic endothelial cells. Furthermore, our
results also indicate that CD73-derived adenosine has a
minor involvement in this process as CD73-deficient
mice only display a slight alteration in the recruitment of
lymphatic endothelial cell in the LPS-peritonitis model.
In the B16 melanoma model, host-A2A deficiency
impaired tumor-associated lymphangiogenesis which
resulted in a reduced number of tumor cells disseminat-
ing to the tumor-draining lymph node.
Collectively, our results demonstrate that the A2A
receptor promotes inflammatory and tumor-associated
lymphangiogenesis.
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